profit from every $100 of sales.
$0$100
Intensity Therapeutics
$3.08-0.65% today
-74.2% in 1 year
1-year low $3.001-year high $14.75
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Intensity Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$11.6 million of profit last year.
SalesProfit
Intensity Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Intensity Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Intensity Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -8 | -8 | -17 | -12 | |
| -8 | -10 | -17 | -12 | |
| -8 | -11 | -16 | -12 | |
| -54.73 | -34.50 | -29.24 | -8.56 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 2 | 17 | 5 | 14 |
| Cash | 1 | 9 | 3 | 12 |
| Total debt | 4 | 0 | 0 | 0 |
| Total liabilities | 17 | 4 | 2 | 2 |
| -15 | 13 | 3 | 12 | |
| 1 | 0 | 1 | 1 | |
| – | -60.7% | -428.7% | -78.9% | |
| 50.2% | -80.1% | -557.5% | -97.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -5 | -7 | -15 | -9 | |
| – | – | – | – | |
| -5 | -7 | -15 | -9 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 1 | 3 | 2 |
Valuation
- –
- –
- –
- 12.9×
- –
- –
- 0.1×
- -90.8%
- -114.1%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -110.1%
- -102.5%
- -136.8%
- -87.0%
- -110.5%
- –
Growth
- –
- –
- +39.3%
- –
- +215.8%
Financial health
- 1.2×
- 0.01
- 0.8%
- –
- 4.86
- 4.86
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 875
Bottom 1%of 987
What analysts expect
- Average price target
- $125.00
- Range
- $125.00 – $125.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.96 | -1.19 | +19.3% |
| Mar 27, 2026 | -1.69 | -1.24 | −36.3% |
| Nov 6, 2025 | -0.06 | -0.06 | +0.0% |
| Aug 7, 2025 | -0.13 | -0.06 | −116.7% |
| May 13, 2025 | -0.22 | -0.21 | −4.8% |
| Mar 13, 2025 | -0.22 | -0.23 | +4.3% |
| Nov 13, 2024 | -0.25 | -0.27 | +7.4% |
| Aug 8, 2024 | -0.36 | -0.32 | −12.5% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
35No pass
Benjamin Graham
43No pass
Philip Fisher
37No pass
Peter Lynch
60Pass
Joel Greenblatt
50No pass
Charlie Munger
30No pass
Terry Smith
27No pass
Questions about Intensity Therapeutics
Is Intensity Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Intensity Therapeutics AI analysis
What does Intensity Therapeutics do?
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. It is in Biotechnology.
Does Intensity Therapeutics pay a dividend?
No. Intensity Therapeutics does not pay a dividend at the moment.
Is Intensity Therapeutics stock halal?
No. Intensity Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 117% of its market value, at or above the 33% limit. How we check
How has Intensity Therapeutics stock done over the past year?
Down 74.2% over the past twelve months, to $3.08. It traded between $3.00 and $14.75 and is 79.1% below its high.
Who are Intensity Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Intensity Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.